Cooperative Agreement UH3CA283652
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $2.2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $405,599 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Think Therapeutics, Inc. to advance next-generation cancer vaccines with superior immunogenic payloads for KRAS mutations. The project aims to characterize the immunogenicity of novel vaccine products and evaluate the cross-reactivity of T cell responses that recognize tumor-presented neoepitopes, leveraging the development of programmable mRNA vaccine...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
- This $414,803 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Massachusetts Institute of Technology (MIT) to develop improved T cell receptor (TCR) engineering strategies for TCR-T cell cancer immunotherapy. The key products and services to be delivered under this grant include: Implementing high-throughput library screens of TCR constant region variants to identify mutations that can improve TCR signaling strength, with...
- This Project Grant award, valued at $411,152, was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The grant supports research at Duke University to identify and validate non-covalent interacting proteins of mutant KRAS inhibitors, which are critical for developing effective therapies for lung, pancreatic, and colorectal cancers driven by oncogenic KRAS mutations. The research aims to utilize mass spectrometry-based proteomics...
- The National Cancer Institute awarded a $269,280 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Cold Spring Harbor Laboratory, a non-profit research institution. The grant supports the development of a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The project aims to create prodrug molecules that can selectively degrade the K-RAS(G12C) protein and release cytotoxic polypharmaceuticals to concurrently target multiple pathways. The key...
- This Project Grant award of $435,827, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate methods for enhancing the effectiveness of KRAS inhibitor cancer therapies. The research aims to identify synthetic lethal genetic interactions that could be leveraged to improve outcomes for patients with KRAS-mutated cancers, which are common in lung, colorectal, and pancreatic...
- The National Cancer Institute awarded a $406,500 Project Grant to Trethera Corp under the Cancer Treatment Research program (CFDA 93.395) to fund the development of a novel, targeted small molecule inhibitor called TRE-515. The goal is to establish the deoxycytidine kinase (DCK) enzyme as a targetable resistance mechanism for KRAS inhibitors in non-small-cell lung cancer (NSCLC) models. The research will evaluate the improved efficacy of KRAS inhibitors when combined with TRE-515 in KRAS-G12C...
- This federal Project Grant award for $657,776.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), will support the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The University of Pittsburgh, as the awardee, will engineer the anthrax toxin protein delivery system and the DUF5 toxin effector domain to create a potent and tumor-selective RAS inactivator. This innovative approach aims to address the...
- This $607,849 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research at Weill Medical College of Cornell University to investigate mechanisms of genetic and non-genetic resistance to KRAS inhibitor drugs for the treatment of lung and colorectal cancers. The research aims to define how cancer cells can develop resistance to KRAS-targeted therapies, including through inflammatory gene expression pathways. The project will...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $2,054,733 in funding to The General Hospital Corporation (doing business as Massachusetts General Hospital) for a project titled "CAR T Cells Targeting Mesothelin and Secreting Bispecific Antibodies Targeting Fibroblasts in Pancreatic Cancer." The project aims to address key limitations of CAR T cell therapy for solid tumors by developing a novel approach using...